Literature DB >> 27007278

Altered primary chromatin structures and their implications in cancer development.

Angelo Ferraro1,2.   

Abstract

BACKGROUND: Cancer development is a complex process involving both genetic and epigenetic changes. Genetic changes in oncogenes and tumor-suppressor genes are generally considered as primary causes, since these genes may directly regulate cellular growth. In addition, it has been found that changes in epigenetic factors, through mutation or altered gene expression, may contribute to cancer development. In the nucleus of eukaryotic cells DNA and histone proteins form a structure called chromatin which consists of nucleosomes that, like beads on a string, are aligned along the DNA strand. Modifications in chromatin structure are essential for cell type-specific activation or repression of gene transcription, as well as other processes such as DNA repair, DNA replication and chromosome segregation. Alterations in epigenetic factors involved in chromatin dynamics may accelerate cell cycle progression and, ultimately, result in malignant transformation. Abnormal expression of remodeler and modifier enzymes, as well as histone variants, may confer to cancer cells the ability to reprogram their genomes and to yield, maintain or exacerbate malignant hallmarks. At the end, genetic and epigenetic alterations that are encountered in cancer cells may culminate in chromatin changes that may, by altering the quantity and quality of gene expression, promote cancer development.
METHODS: During the last decade a vast number of studies has uncovered epigenetic abnormalities that are associated with the (anomalous) packaging and remodeling of chromatin in cancer genomes. In this review I will focus on recently published work dealing with alterations in the primary structure of chromatin resulting from imprecise arrangements of nucleosomes along DNA, and its functional implications for cancer development.
CONCLUSIONS: The primary chromatin structure is regulated by a variety of epigenetic mechanisms that may be deregulated through gene mutations and/or gene expression alterations. In recent years, it has become evident that changes in chromatin structure may coincide with the occurrence of cancer hallmarks. The functional interrelationships between such epigenetic alterations and cancer development are just becoming manifest and, therefore, the oncology community should continue to explore the molecular mechanisms governing the primary chromatin structure, both in normal and in cancer cells, in order to improve future approaches for cancer detection, prevention and therapy, as also for circumventing drug resistance.

Entities:  

Keywords:  Cancer; Chromatin remodeling; Epigenetics; Histone modifications; Histone variants; Nucleosomes

Mesh:

Substances:

Year:  2016        PMID: 27007278     DOI: 10.1007/s13402-016-0276-6

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  161 in total

Review 1.  Multiple roles for ISWI in transcription, chromosome organization and DNA replication.

Authors:  Davide F V Corona; John W Tamkun
Journal:  Biochim Biophys Acta       Date:  2004-03-15

Review 2.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

3.  The human SRCAP chromatin remodeling complex promotes DNA-end resection.

Authors:  Shunli Dong; Jinhua Han; Hongxia Chen; Ting Liu; Michael S Y Huen; Yeran Yang; Caixia Guo; Jun Huang
Journal:  Curr Biol       Date:  2014-08-28       Impact factor: 10.834

4.  MTA1, a transcriptional activator of breast cancer amplified sequence 3.

Authors:  Anupama E Gururaj; Rajesh R Singh; Suresh K Rayala; Caroline Holm; Petra den Hollander; Hao Zhang; Seetharaman Balasenthil; Amjad H Talukder; Goran Landberg; Rakesh Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

5.  A high-resolution atlas of nucleosome occupancy in yeast.

Authors:  William Lee; Desiree Tillo; Nicolas Bray; Randall H Morse; Ronald W Davis; Timothy R Hughes; Corey Nislow
Journal:  Nat Genet       Date:  2007-09-16       Impact factor: 38.330

6.  RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.

Authors:  Julie Caramel; Frédérique Quignon; Olivier Delattre
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.

Authors:  Constanza Cortés; Sara C Kozma; Albert Tauler; Santiago Ambrosio
Journal:  Cell Oncol (Dordr)       Date:  2015-08-26       Impact factor: 6.730

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.

Authors:  Chiara Vardabasso; Alexandre Gaspar-Maia; Dan Hasson; Sebastian Pünzeler; David Valle-Garcia; Tobias Straub; Eva C Keilhauer; Thomas Strub; Joanna Dong; Taniya Panda; Chi-Yeh Chung; Jonathan L Yao; Rajendra Singh; Miguel F Segura; Barbara Fontanals-Cirera; Amit Verma; Matthias Mann; Eva Hernando; Sandra B Hake; Emily Bernstein
Journal:  Mol Cell       Date:  2015-06-04       Impact factor: 17.970

10.  Reptin regulates DNA double strand breaks repair in human hepatocellular carcinoma.

Authors:  Anne-Aurélie Raymond; Samira Benhamouche; Véronique Neaud; Julie Di Martino; Joaquim Javary; Jean Rosenbaum
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

View more
  23 in total

1.  Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.

Authors:  Sirichat Kaowinn; Seung Won Jun; Chang Seok Kim; Dong-Myeong Shin; Yoon-Hwae Hwang; Kyujung Kim; Bosung Shin; Chutima Kaewpiboon; Hyeon Hee Jeong; Sang Seok Koh; Oliver H Krämer; Randal N Johnston; Young-Hwa Chung
Journal:  Cell Oncol (Dordr)       Date:  2017-08-03       Impact factor: 6.730

Review 2.  The emerging role of lncRNAs in the regulation of cancer stem cells.

Authors:  Rosario Castro-Oropeza; Jorge Melendez-Zajgla; Vilma Maldonado; Karla Vazquez-Santillan
Journal:  Cell Oncol (Dordr)       Date:  2018-09-14       Impact factor: 6.730

3.  Real-time visualization of chromatin modification in isolated nuclei.

Authors:  Luca Sardo; Angel Lin; Svetlana Khakhina; Lucas Beckman; Luis Ricon; Weam Elbezanti; Tara Jaison; Harshad Vishwasrao; Hari Shroff; Christopher Janetopoulos; Zachary A Klase
Journal:  J Cell Sci       Date:  2017-07-25       Impact factor: 5.285

Review 4.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

5.  Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome.

Authors:  Christophe Van Neste; Alexander Laird; Fiach O'Mahony; Wim Van Criekinge; Dieter Deforce; Filip Van Nieuwerburgh; Thomas Powles; David J Harrison; Grant D Stewart; Tim De Meyer
Journal:  Cell Oncol (Dordr)       Date:  2017-01-10       Impact factor: 6.730

6.  Identification of genetic variation in the lncRNA HOTAIR associated with HPV16-related cervical cancer pathogenesis.

Authors:  Sweta Sharma Saha; Rahul Roy Chowdhury; Nidhu Ranjan Mondal; Biman Chakravarty; Tanmay Chatterjee; Sudipta Roy; Sharmila Sengupta
Journal:  Cell Oncol (Dordr)       Date:  2016-09-28       Impact factor: 6.730

7.  Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.

Authors:  Zaynab Mousavian; Abbas Nowzari-Dalini; Ronald W Stam; Yasir Rahmatallah; Ali Masoudi-Nejad
Journal:  Cell Oncol (Dordr)       Date:  2016-10-31       Impact factor: 6.730

8.  miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.

Authors:  Laura Pazzaglia; Chiara Novello; Amalia Conti; Serena Pollino; Piero Picci; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2016-11-29       Impact factor: 6.730

9.  Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Authors:  Mikkel Staberg; Signe Regner Michaelsen; Rikke Darling Rasmussen; Mette Villingshøj; Hans Skovgaard Poulsen; Petra Hamerlik
Journal:  Cell Oncol (Dordr)       Date:  2016-10-20       Impact factor: 6.730

Review 10.  Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.

Authors:  Antonieta Chavez-Gonzalez; Babak Bakhshinejad; Katayoon Pakravan; Monica L Guzman; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2016-09-27       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.